Nuclear factor NF-kappa-B subunit 2 (NFKB2)

Nuclear factor NF-kappa-B subunit 2 (NFKB2) is a pivotal transcription factor that serves as the central component of the non-canonical (alternative) NF-kappa-B signaling pathway. It is synthesized as a 100 kDa precursor protein (p100) that acts as an internal inhibitor by sequestering NF-kappa-B subunits in the cytoplasm. Upon activation by specific immune stimuli such as BAFF or CD40 ligand, p100 is phosphorylated by the NIK/IKK-alpha complex, triggering its proteasomal processing into the active 52 kDa subunit (p52). The resulting p52/RelB heterodimers translocate to the nucleus to regulate genes essential for B-cell maturation, lymphoid organogenesis, and immune homeostasis. Dysregulation of NFKB2 is linked to a variety of human diseases; gain-of-function mutations or overactivation are associated with lymphoid malignancies and chronic inflammation, while loss-of-function mutations cause primary immunodeficiencies like Common Variable Immunodeficiency 10 (CVID10) and DAVID syndrome. Therapeutic strategies targeting NFKB2 often utilize proteasome inhibitors to block p100 processing or experimental small molecules targeting upstream kinases to modulate aberrant immune responses in cancer and autoimmunity.

Other names

Nuclear factor NF-kappa-B p100 subunitNuclear factor NF-kappa-B p52 subunitDNA-binding factor KBF2H2TF1Lymphocyte translocation chromosome 10 proteinOncogene Lyt-10Lyt10Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2

Inhibition of the ubiquitin-proteasome system to prevent the proteolytic processing of the p100 precursor into the active p52 subunit; inhibition of upstream kinases such as NIK and IKK-alpha to block the non-canonical NF-kappa-B signaling pathway; and direct interference with DNA binding or nuclear translocation of p52-containing dimers.